News

Machine learning study initiated at the Wyss Institute in collaboration with Google Research enables unprecedented AAV capsid diversification with potential for improving gene therapies.

Melatonin administration proved to be an independent prognostic factor and reduced the risk of death of prostate cancer patients in a retrospective study of 955 patients.

Bone marrow transplant can be a lifesaving procedure for patients with blood cancers. However, graft-versus-host disease (GVHD) is a potentially fatal side effect of transplantation, and it has limited treatment options. The severity of GVHD may be reduced by a single strain of bacteria.

Scientists have identified a pathway that all filoviruses, including Ebola, use to gain entry into our cells and shown how they can be stopped in their tracks by at least one FDA-approved drug.

Researchers have developed a second-generation lung-on-chip model with life-size dimension alveoli in a stretchable membrane, made of purely biological material. The new model reproduces key aspects of the lung tissue architecture not found in previous lungs-on-chip, opening up new possibilities for basic pneumological research, understanding lung pathologies, drug screening and precision medicine.

The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake. New research suggests that the GIP receptor could be a potential therapeutic target for obesity and Type 2 diabetes.

Longstanding obstacles to include pregnant and lactating people in clinical research have led to this population now deciding whether or not to receive a SARS-CoV-2 vaccine without the benefit of scientific evidence, scientists say.

The first approved therapeutic antibody against B tumor cells was rituximab, an anti-cancer drug targeting the membrane protein CD20. Now, a team of immunologists has solved the mystery about how it works.

A double-blind Phase 3 international trial investigated whether semaglutide could help to reduce boy weight in overweight individuals. A third of participants who took the drug lost more than twenty percent of their total body weight.

For a drug to be effective at the right places in the body, it can help if it can be predicted accurately how the molecules of that drug will interact with human cells. For the first time, a blueprint of the neuropeptide Y receptor Y2 with one of its ligands is available, enabling the development of tailor-made drugs, for example, to treat epilepsy or cardiovascular diseases.